Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way ...

16 In the future, CRISPR diagnostics have the potential to transform the field of personalized medicine. By enabling the rapid and precise identification of genetic predispositions, these tools ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day. ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

Today’s headlines highlight critical developments in genetic medicine, global politics, and the latest updates from the ...